Analyst on an average had expected profit of Rs 82 from the biotechnology firm. The company had posted a net profit of Rs 79 crore in the same quarter last fiscal.
Consolidated total income of the company increased by 21% to Rs 701 crore in Q1 FY2014 quarter as against Rs 577 crore for the year ago period. EBITDA margins improved to 21.69% from 21.28% over the corresponding quarter of previous fiscal, Biocon said in a statement.
The stock opened at Rs 310 and hit a high of Rs 316, nears to its 52-week high of Rs 322 touched on November 16, last year. A combined 739,478 shares changed hands on the counter till 1046 hours on NSE and BSE.